Alzamend Neuro, Inc.

NasdaqCM: ALZN · Healthcare

Positivity Index

#4,299 / 6,774

Global

#2,112 / 4,000

United States

Positivity Score

19,651

Rank→

PosiRed: 2 active red flags (highest severity 6/10) · PosiYellow: 1 yellow flag (1/10 points) View flag history →

PosiRed · red flag

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 03 Aug 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

More details →

PosiRed · red flag

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 20 Mar 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

More details →

PosiYellow · yellow flag (stress signal)

Pledge-related SEC filings found

Found 1 SEC Form 4 filing(s) mentioning 'pledged' for this company's insiders. No exact percentage is available from this source (unlike India's BSE disclosures) — this flags that pledge-related activity exists and is worth reviewing directly on SEC EDGAR, not a computed magnitude.

More details →

Alzamend Neuro, Inc. — Overview & Financial Snapshot

Alzamend Neuro, Inc. (NasdaqCM: ALZN) is a Healthcare company, ranked #4,299 of 6,774 companies globally and #2,112 of 4,000 in United States on PositoAI, with a Positivity Score of 19,651. Its market capitalisation is ₹51.02 Cr ($5.40M), P/E ratio is -0.5 and P/B ratio is 0.93. It currently has 2 active red flags (PosiRed) and 1 yellow flag (PosiYellow, 1/10 points) on record.

For financial statements, ratio trends and score history, Go Deep →

What does Alzamend Neuro, Inc. do?

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of…

What is Alzamend Neuro, Inc.'s P/E and P/B ratio?

Alzamend Neuro, Inc. has a P/E ratio of -0.5 and a P/B ratio of 0.93.

What is Alzamend Neuro, Inc.'s debt-to-equity ratio?

Alzamend Neuro, Inc. has a debt-to-equity ratio of 0.00.

How much does Alzamend Neuro, Inc. owe compared with what it owns?

Alzamend Neuro, Inc. owes $0.32 for every $1 it owns (balance sheet Jul 2026), which is low.

What is Alzamend Neuro, Inc.'s Positivity rank?

Alzamend Neuro, Inc. is ranked #4,299 of 6,774 companies globally and #2,112 of 4,000 in United States on PositoAI, with a Positivity Score of 19,651.

Does Alzamend Neuro, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

Yes. Alzamend Neuro, Inc. has 2 active red flags (PosiRed) on record: Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 03 Aug 2026); Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 20 Mar 2026). It also has 1 yellow flag (PosiYellow stress signals, 1/10 points): Pledge-related SEC filings found.

Where can I read the latest news about Alzamend Neuro, Inc.?

Recent headlines about Alzamend Neuro, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Alzamend Neuro, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Alzamend Neuro, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.